Home/Pipeline/p70 S6 Kinase Inhibitor

p70 S6 Kinase Inhibitor

Fragile X Syndrome

PreclinicalActive

Key Facts

Indication

Fragile X Syndrome

Phase

Preclinical

Status

Active

Company

Epigen Biosciences

About Epigen Biosciences

Epigen Biosciences is a preclinical biotech firm leveraging a multi-target approach to develop novel therapeutics for fibrotic and neurodegenerative diseases with high unmet need. Its pipeline is built on three core platforms: an LPA1 receptor antagonist for fibrosis, sigma-1 receptor ligands for neurodegeneration, and a p70 S6 kinase inhibitor for Fragile X Syndrome. The company employs innovative research models, including cerebral organoids, and collaborates with academic institutions like UCSD to advance its programs toward clinical development.

View full company profile

Therapeutic Areas

Neuroscience Rare Disease Fibrosis Nephrology Hepatology Pulmonology

Other Fragile X Syndrome Drugs

Drug	Company	Phase	Status
KER-0193	Kaerus Bioscience	Preclinical	Active
HLX-0206	Healx	AI Discovery	Active
ENT-3379	Enthorin Therapeutics	Phase 1	Active
AUT00206	Autifony Therapeutics	Clinical	Active
Fragile X Program	Sentinel Oncology	Preclinical	Active
Fragile X Syndrome Program	Purposeful	Discovery/Pre-clinical	Active
Fragile X Syndrome Trial	Science 37	Phase 3	Completed/Highlighted
DAYBUE® (trofinetide)	Neuren Pharmaceuticals	Phase 2	Completed
Fragile X Syndrome Test	Genomics BioSci & Tech	Clinical	Active
Xanamem (emestedastat)	Actinogen Medical	Phase 2	Active